NEVRALIP 600 RETARD

30 tablets

Nevralip™ 600 is a Food Supplement based on α-Lipoic Acid, Chromium Picolinate, Vitamins and Minerals. Nevralip™ 600 retard is formulated in a special matrix that allows a prolonged release of the components, in order to overcome a limitation to the use of α-Lipoic Acid, characterised by a short half-life of about 30 minutes.

Nevralip 600 Retard is used in all clinical situations characterised by an altered peripheral nervous trophism. Furthermore, it is used in all those situations of hyperglycemia by improving the sensitivity of cells to insulin and the management of blood sugar.

Description

Nevralip 600 Retard is also used in situations of hyperglycemia, a condition characterized by high levels of glucose in the blood compared to normal values.
Nevralip 600 Retard improves the sensitivity of cells to insulin plus the management of blood sugar.

Lipoic Acid is an endogenous antioxidant capable of preventing the damage caused by oxidative stress.

Lipoic Acid promotes the regeneration of endogenous antioxidants such as Vitamin E, Vitamin C, and Glutathione. Chromium Picolinate is a biologically active organic chromium capable of controlling glucose levels in the blood by increasing the response to insulin binding.

Selenium and Zinc are essential minerals that can improve our Antioxidant defence system.
Of fundamental importance is the presence of Biotin capable of improving skin trophism which becomes compromised when taking long-term α-Lipoic Acid which can block the biosynthesis of endogenous Biotin.

Pharmaceutical form

Tablets - Pack of 30 tablets of 1.15 g each. - Gluten-Free.

Application

We recommend taking 1 tablet a day, preferably on an empty stomach.

Information / Warnings

Food Supplements are not intended as a substitute for a varied, balanced diet and a healthy lifestyle.
Do not exceed the recommended daily dose.
Keep out of the reach of children under 3 years of age.
Do not use during pregnancy and lactation.

Nutritional table

Average contentsfor 1 tablet%VNR*
Lipoic Acid600 mg-
Chromium Picolinate
equal to Chromium
0.8 mg
100 mcg
250
Biotin100 mcg200
Vitamin B63 mg214
Thiamine2 mg-
Pantothenic acid9 mg-
Vitamin E15 mg125
Zinc10 mg100
Selenium50 mcg91


*VNR Nutritional Value of Adult Daily Reference - EU Reg. 1169/2011

You may also be interested in:

River Pharma products represent progress for the Medical-Scientific Community, as well as the response to the most widespread ailments and diseases in the world.

SYALOX 300 PLUS

SYALOX 300 PLUS

Syalox 300 Plus is indicated in all clinical situations characterised by joint pain and reduced mobility.

Discover the product
NEVRALCAR DUO

NEVRALCAR DUO

The Synergy of the 2 Active Ingredients allow pain control in all those clinical situations characterized by Neuropathy of both joint and metabolic origin.

Discover the product

River Pharma: Healthcare is Our Passion

Nutraceuticals

State-of-the-art products based on high molecular weight Hyaluronic Acid obtained through bio-fermentation technology and are characterised by their effectiveness proven in five distinct therapeutic areas.

Find out more

Medical Devices

The latest generation of medical devices based on Hyaluronic Acid with a high molecular weight, 2 mil D, to be injected, effective for the treatment and prevention of osteoarticular pathologies linked to ageing and for the treatment of acute trauma. 

Find out more

Dermocosmetics

Products that contain, Hyaluronic Acids with a careful selection of molecular weight, amongst other things and are characterised by their anti-ageing effectiveness.

Find out more

Science Informs: The River Pharma Blog

Stay up to date, learn more about the research and insights of the most authoritative members of the International Medical-Scientific Community.

Menopause and osteoporosis: what causes bone loss?

Menopause and osteoporosis: what causes bone loss?

Unfortunately for all women who are in menopause osteoporosis is a sad reality that sooner or later will become increasingly present in their lives, this is even more true in all those who already have a genetic predisposition towards this degenerative bone disease.

Keep reading

Iscriviti alla nostra Newsletter

Il tuo appuntamento con la Scienza non si ferma mai. Registrati e rimani sempre aggiornato sulle notizie, gli approfondimenti, gli studi e le soluzioni terapeutiche più all’avanguardia.